INDICATION(S)
The FUMIR regimen (Table 1) is used as primary therapy of nonmetastatic cancer of the anal canal. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Current guidelines list mitomycin plus fluorouracil administered concurrently with radiation as initial treatment of nonmetastatic anal canal cancer. 1
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing fluorouracil or mitomycin. A. Fluorouracil 1. Use fluorouracil 50 mg/mL injection. 2. Dilute in 500 to 1,000 mL of 0.9% sodium chloride injection (NS), 5% dextrose injection (D5W), or a saline/dextrose solution for injection. 3. Fluorouracil may be diluted to a final volume of 60 to 150 mL with bacteriostatic 0.9% sodium chloride injection (BNS) for administration by an ambulatory infusion pump. B. Mitomycin 1. Use mitomycin powder for injection.
2. Dilute with NS, D5W, or sterile water for injection to a concentration of 0.5 to 1 mg/mL. 3. Dispense in a syringe for injection, or dilute in 50 to 100 mL of NS, D5W, or a saline/dextrose solution for infusion. 
DRUG ADMINISTRATION

SUPPORTIVE CARE
A. Acute Emesis Prophylaxis: The FUMIR regimen is predicted to cause acute emesis in 10% to 30% of patients on day 1 and less than 10% of patients on days 2 through 4. 14, 15 The studies reviewed reported grade 1 or 2 emesis in 19% of patients. 12 Grade 3 or 4 emesis was reported in 3% to 6% of patients. 12, 13 Appropriate acute emesis prophylaxis includes a corticosteroid or a dopamine receptor antagonist. 14 One of the following regimens is suggested: 1. Dexamethasone 12 mg orally (PO) given 30 minutes before day 1 of FUMIR.
2. Metoclopramide 10 to 40 mg PO given 30 minutes before day 1 of FUMIR. 3. Prochlorperazine 10 mg PO given 30 minutes before day 1 of FUMIR. Should the above regimens be insufficient for acute emesis prophylaxis, a serotonin (5-HT3) antagonist and corticosteroid combination can be used. The following regimens are recommended: 1. Ondansetron 16 mg to 24 mg and dexamethasone 12 mg, both given PO 30 minutes before day 1 of FUMIR. 2. Granisetron 2 mg and dexamethasone 12 mg, both given PO 30 minutes before day 1 of FUMIR. 3. Dolasetron 100 mg and dexamethasone 12 mg, both given PO 30 minutes before day 1 of FUMIR. 4. Palonosetron 0.25 mg IV and dexamethasone 12 mg PO, both given 30 minutes before day 1 of FUMIR. B. Breakthrough Nausea and Vomiting 14 : Patients should receive an antiemetic prescription to treat breakthrough nausea and vomiting. 14 guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 16 Because febrile neutropenia was reported in 15% to 18% of patients and fatal neutropenic sepsis was reported in 3% of patients treated with the FUMIR regimen, prophylactic use of CSFs may be considered. 2, 12 D. Diarrhea: Diarrhea is a frequent consequence of protracted venous infusion of fluorouracil and is less common with bolus administration. Diarrhea is usually mild to moderate, responding to conventional therapy. Occasionally the problem can be severe or dose-limiting. In the studies reviewed, grade 2 diarrhea was reported in 15% to 94% of patients, grade 3 diarrhea was reported in 2% to 20% of patients, and grade 4 diarrhea was reported in 1% of patients receiving FUMIR. 3, [9] [10] [11] [12] [13] Patients should receive a prescription for an antidiarrheal agent for use at the onset of diarrhea. The standard recommendation is loperamide 4 mg PO at the onset of diarrhea, followed by 2 mg PO Variations 1. Fluorouracil 750 mg/m 2 daily on days 1-5 and days 29-33, and a single dose of mitomycin 15 mg/m 2 on day 1 of radiation. 3 2. Fluorouracil 1,000 mg/m 2 daily on days 1-4 and days 29-33, and a single dose of mitomcyin 10 to 15 mg/m 2 on day 1 of radiation. 4 3. Fluorouracil 200 mg/m 2 /day by continuous infusion on days 1-26, and a single dose of mitomycin 10 mg/m 2 on day 1. 9 4. Fluorouracil 750 mg/m 2 on days 1-5, and a single dose of mitomycin 15 mg/m 2 on day 1. 11 5. Fluorouracil 200 mg/m 2 on days 1-26 of radiation sequence 1, 200 mg/m 2 on days 1-17 of radiation sequence 2, and mitomycin 10 mg/m 2 on day 1 of each radiation sequence. 13 6. Regimen above, fluorouracil capped at 1,500 mg per day. 5, 6 7. Fluorouracil 1,000 mg/m 2 daily on days 1-4 and mitomycin 10 mg/m 2 on day 1 of radiation. 7
Note: CIVI 5 continuous intravenous infusion; Gy 5 Gray; IV 5 intravenous. every after each unformed stool or as often as every 2 hours for 24 hours. 17 Patients should be counseled to 18 : 1. Monitor bowel movements. 2. Treat grade 1 or 2 diarrhea (increase of ,7 stools per day or nocturnal stools) with loperamide and oral rehydration. 3. Immediately seek advice from their physician, pharmacist, or nurse for persistent (.24 hours) grade 1 or 2 diarrhea or grade 3 diarrhea (increase of $7 stools per day, incontinence, or symptoms of dehydration).
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Cardiac arrhythmias (grade 1 or 2) 2%, 12 (grade 3 or 4) 1% 12 ; cardiac failure (all grades) 2% 2 ; cardiovascular dysfunction not requiring discontinuation of therapy (grade 1 or 2) 13%, 12 (grade 3 or 4) 4% 12 ; coagulopathy (any) (grade 1 or 2) 1% 12 ; hemorrhage (grade 1 or 2) 12%, 12 (grade 3 or 4) 1% 12 ; stroke (all grades) 2%. 4 B. Constitutional symptoms: Pain (grade 1 or 2) 29%, 12 (grade 3 or 4) 24% 12 ; unspecified constitutional symptoms (grade 1 or 2) 24 to 59%, 12 (grade 3 or 4) 8 to 10%. 12 C. Dermatologic: Dermatitis (grade 1 or 2) 4% to 51%, 11 (grade 3) 5% 11 ; extravasation causing skin necrosis (all grades) 4% 11 ; genital dermatitis (grade 3) 15% 13 ; inguinal dermatitis (grade 3) 5% 13 ; moist desquamation (grade 3) 20% 8 ; perianal dermatitis (grade 2) 28% 9 ; ulcer (all grades) 0.03% to 9% 8, 9 ; unspecified skin toxicity (grade 1 or 2) 9% to 42%. 3,9,10 D. Endocrine: Endocrine toxicity (any) (grade 1 or 2) 2%. 12 E. Gastrointestinal: Anorectal soft tissue toxicity (all grades) 21% 5 ; bowel occlusion 0.2% (all grades) 9 ; diarrhea (grade 1 or 2) 2% to 96%, 3,10-12 (grade 3 or 4) 2% to 23% 3, 9, [11] [12] [13] ; mucosal reaction (all grades) 2% 3 ; nausea (grade 1 or 2) 49%, 12 (grade
